ArticleClinical cancer research : an official journal of the American Association for Cancer Research2024

FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma.

Deepti Telaraja et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.